Trial Profile
A Multi-Center, Open-Label, Randomized, Active-Control, Parallel-Group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug Naive Type 2 Diabetes Mellitus Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Nateglinide (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ENERGY-1
- Sponsors Novartis
- 19 Jul 2012 Results published in Current Medical Research and Opinion.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 13 Jun 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.